Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma
Regina M Myers,Brian T Hill,Bronwen E Shaw,Soyoung Kim,Heather R Millard,Minoo Battiwalla,Navneet S Majhail,David Buchbinder,Hillard M Lazarus,Bipin N Savani,Mary E D Flowers,Anita D'Souza,Matthew J Ehrhardt,Amelia Langston,Jean A Yared,Robert J Hayashi,Andrew Daly,Richard F Olsson,Yoshihiro Inamoto,Adriana K Malone,Zachariah DeFilipp,Steven P Margossian,Anne B Warwick,Samantha Jaglowski,Amer Beitinjaneh,Henry Fung,Kimberly A Kasow,David I Marks,Jana Reynolds,Keith Stockerl-Goldstein,Baldeep Wirk,William A Wood,Mehdi Hamadani,Prakash Satwani
DOI: https://doi.org/10.1002/cncr.31114
IF: 6.9209
2018-02-15
Cancer
Abstract:Background: Autologous hematopoietic cell transplantation (auto-HCT) is a standard therapy for relapsed classic Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL); however, long-term outcomes are not well described. Methods: This study analyzed survival, nonrelapse mortality, late effects, and subsequent malignant neoplasms (SMNs) in 1617 patients who survived progression-free for ≥2 years after auto-HCT for cHL or DLBCL between 1990 and 2008. The median age at auto-HCT was 40 years; the median follow-up was 10.6 years. Results: The 5-year overall survival rate was 90% (95% confidence interval [CI], 87%-92%) for patients with cHL and 89% (95% CI, 87%-91%) for patients with DLBCL. The risk of late mortality in comparison with the general population was 9.6-fold higher for patients with cHL (standardized mortality ratio [SMR], 9.6) and 3.4-fold higher for patients with DLBCL (SMR, 3.4). Relapse accounted for 44% of late deaths. At least 1 late effect was reported for 9% of the patients. A total of 105 SMNs were confirmed: 44 in the cHL group and 61 in the DLBCL group. According to a multivariate analysis, older age, male sex, a Karnofsky score < 90, total body irradiation (TBI) exposure, and a higher number of lines of chemotherapy before auto-HCT were risk factors for overall mortality in cHL. Risk factors in DLBCL were older age and TBI exposure. A subanalysis of 798 adolescent and young adult patients mirrored the outcomes of the overall study population. Conclusions: Despite generally favorable outcomes, 2-year survivors of auto-HCT for cHL or DLBCL have an excess late-mortality risk in comparison with the general population and experience an assortment of late complications. Cancer 2018;124:816-25. © 2017 American Cancer Society.